376 related articles for article (PubMed ID: 25628464)
1. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
[TBL] [Abstract][Full Text] [Related]
2. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
[TBL] [Abstract][Full Text] [Related]
3. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
[TBL] [Abstract][Full Text] [Related]
4. Use of nitisinone in patients with alkaptonuria.
Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low dose nitisinone in the management of alkaptonuria.
Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
[TBL] [Abstract][Full Text] [Related]
8. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
[TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.
Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T
J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729
[TBL] [Abstract][Full Text] [Related]
10. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.
Introne WJ; Perry MB; Troendle J; Tsilou E; Kayser MA; Suwannarat P; O'Brien KE; Bryant J; Sachdev V; Reynolds JC; Moylan E; Bernardini I; Gahl WA
Mol Genet Metab; 2011 Aug; 103(4):307-14. PubMed ID: 21620748
[TBL] [Abstract][Full Text] [Related]
11. Natural history of alkaptonuria.
Phornphutkul C; Introne WJ; Perry MB; Bernardini I; Murphey MD; Fitzpatrick DL; Anderson PD; Huizing M; Anikster Y; Gerber LH; Gahl WA
N Engl J Med; 2002 Dec; 347(26):2111-21. PubMed ID: 12501223
[TBL] [Abstract][Full Text] [Related]
12. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
[TBL] [Abstract][Full Text] [Related]
13. Alkaptonuria.
Yancovitz M; Anolik R; Pomeranz MK
Dermatol Online J; 2010 Nov; 16(11):6. PubMed ID: 21163157
[TBL] [Abstract][Full Text] [Related]
14. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
15. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
[TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures.
Prieto JA; Andrade F; Lage S; Aldámiz-Echevarría L
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):671-6. PubMed ID: 21377430
[TBL] [Abstract][Full Text] [Related]
18. Preventive use of nitisinone in alkaptonuria.
Wolffenbuttel BHR; Heiner-Fokkema MR; van Spronsen FJ
Orphanet J Rare Dis; 2021 Aug; 16(1):343. PubMed ID: 34344451
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
Ranganath LR; Psarelli EE; Arnoux JB; Braconi D; Briggs M; Bröijersén A; Loftus N; Bygott H; Cox TF; Davison AS; Dillon JP; Fisher M; FitzGerald R; Genovese F; Glasova H; Hall AK; Hughes AT; Hughes JH; Imrich R; Jarvis JC; Khedr M; Laan D; Le Quan Sang KH; Luangrath E; Lukáčová O; Milan AM; Mistry A; Mlynáriková V; Norman BP; Olsson B; Rhodes NP; Rovenský J; Rudebeck M; Santucci A; Shweihdi E; Scott C; Sedláková J; Sireau N; Stančík R; Szamosi J; Taylor S; van Kan C; Vinjamuri S; Vrtíková E; Webb C; West E; Záňová E; Zatkova A; Gallagher JA
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):762-772. PubMed ID: 32822600
[TBL] [Abstract][Full Text] [Related]
20. Method development and validation for analysis of phenylalanine, 4-hydroxyphenyllactic acid and 4-hydroxyphenylpyruvic acid in serum and urine.
Hughes AT; Milan AM; Shweihdi E; Gallagher J; Ranganath L
JIMD Rep; 2022 Jul; 63(4):341-350. PubMed ID: 35822095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
